Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase II clinical trial

Gabriela L. Ferrel; Feifan Zhou; Xiaosong Li; Tomas Hode; Robert E. Nordquist; Luciano Alleruzzo; Wei R. Chen

doi:10.1117/12.2041263

13 March 2014 Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase II clinical trial

Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Tomas Hode, Robert E. Nordquist, Luciano Alleruzzo, Wei R. Chen

Author Affiliations +

Proceedings Volume 8944, Biophotonics and Immune Responses IX; 89440I (2014) https://doi.org/10.1117/12.2041263
Event: SPIE BiOS, 2014, San Francisco, California, United States

Abstract

Laser immunotherapy (LIT), a novel technique with a local intervention to induce systemic antitumor effects, was developed to treat metastatic cancers. The pre-clinical studies of LIT have shown its unique characteristics in generating a specific antitumor immunity in treating metastatic tumors in rats and mice. For late-stage, metastatic breast cancer patients, who were considered to be out of other available treatment options, we conducted a small Phase II clinical trial using LIT starting in 2009 in Lima, Peru. This Phase II study was closed in December of 2012, as acknowldged by the Ministry of Health (MOH) of Peur letter 438-2014-OGITT/INS dated March 5^th, 2014. Ten patients were enrolled and received LIT in one or multiple 4-week treatment cycles. At the study closing date, four patients were alive and two of them remained cancer free. Here, following the successful conclusion of our Phase II study, we report the clinical effects of LIT on metastatic breast cancer patients. Specifically, we present the overall status of all the patients three years after the treatment and also the outcomes of two long-term surviving patients.

Citation Download Citation

Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Tomas Hode, Robert E. Nordquist, Luciano Alleruzzo, and Wei R. Chen "Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase II clinical trial", Proc. SPIE 8944, Biophotonics and Immune Responses IX, 89440I (13 March 2014); https://doi.org/10.1117/12.2041263

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available